Zenas BioPharma, Inc. (NASDAQ:ZBIO) Financings

Zenas BioPharma, Inc.

Financings

RaiseDate
Private placement of common stock
Announced: about US$120M · US$19 a share · Jefferies +1
Dealers: Jefferies (co-lead), Evercore ISI (co-lead)
Insiders: Certain directors and officers of the Company participate at a price of $20.85 per share
Oct 8, 2025
Royalty funding (5.5% royalty on worldwide net sales of obexelimab)
Announced: up to US$300M · Evercore
Dealers: Evercore
Buyers: Royalty Pharma plc (up to $300 million in funding in exchange for a 5.5% royalty on worldwide net sales of obexelimab)
Use of proceeds: Obexelimab development and a potential IgG4-RD commercial launch in the first half of 2027, subject to FDA approval
Sep 2, 2025

Read by 6ix AI from the company's releases